Drug Trial Radar · NCT07921420
MF-300 for Treatment of Age-Related Sarcopenia
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Jan 1, 2027
Primary completion
Jun 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Epirium Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2b clinical trial will evaluate whether MF-300 can improve physical function and muscle strength and assess its safety in adults aged 65 years and older with sarcopenia. The study will also evaluate how MF-300 is processed by the body and its effects on measures related to muscle health, quality of life, and physical activity. Participants will receive MF-300 or placebo once daily for 24 weeks. The study includes an initial open-label part evaluating MF-300 followed by a randomized, placebo-controlled part evaluating two dose levels of MF-300.
Conditions
- Sarcopenia in Elderly
Interventions
MF-300Drug
oral tablet at doses of 75mg
PlaceboDrug
matching placebo oral tablet
MF-300Drug
oral tablet at doses of 200 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- 5-times chair stand test (5xCST)Time frame: Baseline, Week 12, and Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.